Post on 30-May-2018
transcript
8/14/2019 braunwalds PCI for AMI
1/44
Where Everyone Has VIP Access!!
8/14/2019 braunwalds PCI for AMI
2/44
8/14/2019 braunwalds PCI for AMI
3/44
PCAT meta-analysisEvidence favoring the primary angioplastystrategy was derived from the PCAT (PrimaryCoronary Angioplasty Trialists) meta-analysis of10 randomized trials (conducted from 1989 to1996).Primary POBA significantly reduced 30-day
mortality (4.4 vs. 6.5%, P=0.02; 34% riskreduction) and the combination of death plusreinfarction (7.2 vs.11.9%, P < 0.001, 40% risk
reduction).These effects were not significantly affected by
the thrombolytic regimen. Primary angioplastywas also associated with a reduction in totalstroke (0.7 vs. 2.0%, P=0.007) and a marked
decrease in hemorrhagic stroke (0.1 vs. 1.1%, P
8/14/2019 braunwalds PCI for AMI
4/44
PCAT AnalysisE
8/14/2019 braunwalds PCI for AMI
5/44
What About Stents vs.
Lytics?These studies were done before the adoption ofmore advanced PCI techniques.More recent trials have compared thrombolysis
with stents and (GP) IIb/IIIa receptor inhibitors.For example, the Stent vs. Thrombolysis forOccluded Coronary Arteries in Patients with AcuteMyocardial Infarction (STOPAMI) trial comparedpatients reperfused with a stent plus abciximabwith patients receiving t-PA.Scintigraphic infarct size was significantly reduced
in the PCI group because of a larger salvageindex. In addition, the composite endpoint ofdeath, reinfarction, and stroke was lower in thestent group (8.5 vs. 23.2% at 6 months, P=0.02).
8/14/2019 braunwalds PCI for AMI
6/44
Review by KeeleyA quantitative review by Keeley has combined the PCATanalysis with 13 more recent investigations (1997 to 2002),in which stents were used in 12 of 13 and GP IIb/IIIainhibitors in 7 of 13 trials.
Of the total group (N
= 7739), most patients (76%)randomized to thrombolytic therapy received t-PA.The summary results a significant reduction in death,
reinfarction, stroke, and hemorrhagic stroke for patientstreated with primary PCI. Major hemorrhage (5 vs. 7%,P=0.032) was the only endpoint increased in the PCIpatients.
The benefit was similar, irrespective of the thrombolyticregimen. The survival advantage for primary PCI overthrombolysis (20 lives saved for every 1000 patientstreated) is similar to the magnitude of benefit forthrombolysis compared to placebo.
Long-term (6 months) outcomes in several trials have beenpersistently favorable for the PCI patients.
8/14/2019 braunwalds PCI for AMI
7/44
Combination Lytic & GPModification of pharmacological reperfusion using
a reduced dose lytic agent and addition of a GPIIb/IIIa inhibitor has resulted in higher TIMI-3 flow
rates.This combination therapy was tested in the
GUSTO-V and ASSENT-3 trials.Despite a decrease in early ischemic events
(including reinfarction), there was no reduction in30-day or 1-year mortality compared withstandard lytic therapy.Combination therapy also increased the risk of
hemorrhage (including intracranial) in elderly
patients.
8/14/2019 braunwalds PCI for AMI
8/44
TIMI Flow GradesGrade 0: No perfusion. There is no antegrade flow beyondthe point of occlusion.
Grade 1: Penetration without perfusion. Contrast materialpasses beyond the area of obstruction but fails to opacify
the entire coronary bed distal to the obstruction for theduration of the cine filming sequence.Grade 2: Partial perfusion. Contrast material passes across
the obstruction and opacifies the coronary distal to theobstruction. However, the rate of entry of contrast materialinto the vessel distal to the obstruction and/or its rate ofclearance from the distal bed (or both) is perceptibly slowerthan its flow into or clearance from comparable areas notperfused by the previously occluded vessel.
Grade 3: Complete perfusion. Antegrade flow into the beddistal to the obstruction occurs as promptly as antegradeflow into the bed proximal to the obstruction, and clearanceof contrast material from the involved bed is as rapid as
clearance from an uninvolved bed in the same vessel or theopposite artery.
8/14/2019 braunwalds PCI for AMI
9/44
TIMI Myocardial PerfusionGrade 0: minimal or no myocardial blush
Grade 1: Dye stains myocardium and stain
persists on the next injectionGrade 2: Dye enters myocardium but washes
out slowly so that the dye is stronglypersistent at the end of the injection.
Grade 3: normal entrance and exit of dye inthe myocardium.
8/14/2019 braunwalds PCI for AMI
10/44
8/14/2019 braunwalds PCI for AMI
11/44
8/14/2019 braunwalds PCI for AMI
12/44
Advantages of the PCI
StrategySuperior Restoration of Flow
Treatment of the Inciting Pathobiology in AMI
Anatomical Definition and Risk StratificationReduction in Complications
8/14/2019 braunwalds PCI for AMI
13/44
Superior Restoration ofFlowCritical link between early establishment of TIMI-3
flow with myocardial salvage and survival.
Primary PCI attains TIMI-3 flow in more than 90%
of patients. In contrast, less than 65% of patients receiving a lytic
agent achieve this benchmark.
Primary PCI efficacy is sustained in the late stagesof infarctionthrombolysis effectiveness declines significantly within a
few hours of symptom onset.
This discrepancy provides a theoretical basis forthe incremental improvement in outcomes withprimary PCI.
8/14/2019 braunwalds PCI for AMI
14/44
Treatment of Inciting
PathobiologyReperfusion therapy (especially thrombolysis)
targets the thrombotic intracoronary eventthat occurs in most myocardial infarctions.
However, dynamic factors, apart fromthrombus, including plaque rupture,intramural hemorrhage, dissection, andspasm, are effectively treated with catheter-based reperfusion and may partially explainthe advantage of primary PCI overthrombolysis.
8/14/2019 braunwalds PCI for AMI
15/44
8/14/2019 braunwalds PCI for AMI
16/44
Reocclusion occurs in 25 to 30% of patientsafter successful thrombolysis. After primaryballoon angioplasty, reocclusion ranges from 5to 16.7%
Stenting further decreases risk of reocclusion(5.1% vs. 9.3% with PTCA.)
8/14/2019 braunwalds PCI for AMI
17/44
Anatomical Definition
and Risk StratificationAngiographic and hemodynamic data obtained at the time
of cath impart valuable decision-facilitating information andmore precise risk stratification.
Angiography defines the coronary anatomy in patients withequivocal or uninterpretable ECG changes.
After urgent coronary angiography, a subset of patients willrequire emergent coronary bypass surgery for severemultivessel or left main coronary artery disease.
Mechanical complications can also be identified duringcardiac catheterization. An additional subset of patientsexhibits spontaneous reperfusion without a significantresidual stenosis and avoids the hazards of re-perfusiontherapy, including the hemorrhagic risks of thrombolysis
8/14/2019 braunwalds PCI for AMI
18/44
Anatomical Definition
and Risk StratificationA primary PCI strategy allows stratification of
patients into a low-risk group (age 70 years,LVEF higher than 0.45, one- or two-vesseldisease, successful angioplasty, no persistentarrhythmias) who can be discharged after 3days with reduced costs and similar survivalcompared with longer hospitalization (7 days).
8/14/2019 braunwalds PCI for AMI
19/44
Reduction inComplications
Treatment with primary angioplasty appears toreduce infarct rupture.
In a combined meta-analysis of the GUSTO-I and
PAMI-I/II trials, primary angioplasty resulted in an86% reduction in the risk of mechanicalcomplications compared with patients undergoingthrombolysis.
There was a significant reduction in acute MR(0.31 vs. 1.73%, P < 0.001) and VSDs (0.0 vs.0.47%, P < 0.001).
In a multivariate analysis of 1375 patients,
treatment with primary angioplasty was
8/14/2019 braunwalds PCI for AMI
20/44
Complications of
Reperfusion TherapyIntracranial hemorrhage may be fatal in half to
two thirds of patients and remains a devastatingperil of thrombolytic therapy.
In a comparative analysis, the risk of intracranialhemorrhage was found to be 1% withthrombolysis and 0.05% with PCI.
Major bleeding complications were increased with
PCI compared with thrombolysis (7 vs. 5%,P=0.032). However, these hemorrhages usuallyoccur at the access site and were found todecrease in later trials.
8/14/2019 braunwalds PCI for AMI
21/44
Temporal Dynamics of
Reperfusion TherapyRapid reperfusion of the infarct artery leading
to myocardial salvage has remained therationale for early reperfusion.
The survival benefit of thrombolyticreperfusion therapy decreases with increasingdelay in treatment.
There is an inherent delay in initiation of
primary PCI reperfusion compared withthrombolysis.
Despite the identified advantages and trialevidence favoring a primary PCI strategy,
considerable controversy still surrounds therelative time-de endent efficac of this
8/14/2019 braunwalds PCI for AMI
22/44
Examination of primary angioplasty (N = 27,080) in the
NRMI-2 database has revealed that the adjusted odds ofhospital mortality did not increase significantly withincreasing time from symptom onset to balloon inflation(ischemic time) but mortality did increase with a door toballoon time (treatment interval) longer than 2 hours.
One large study (N = 2635) has demonstrated increasingmajor adverse cardiac events rates with increasingpresentation delay for thrombolysis but relatively stableevent rates over time for primary angioplasty.
A mechanistic difference in reperfusion efficacy was
illustrated by the study of Schomig and associates, whodemonstrated a consistent degree of myocardial salvagewith primary PCI (stenting), despite increasing ischemictime.
Conversely, myocardial salvage achieved by thrombolysis
declines markedly with increasing ischemic time, leading toa lar er a arent advanta e from rimar PCI with later
8/14/2019 braunwalds PCI for AMI
23/44
LOGISTIC CHALLENGE OF
EFFECTIVE REPERFUSION THERAPY.Despite analytical considerations, the selection of
reperfusion therapy remains a complex and controversialdecision. Local factors, patient risk, and temporal dynamicsmust be considered.
In facilities able to provide on-site primary PCI, expeditiousapplication clearly provides the best opportunity forsurvival.
However, only approximately 25% of U.S. hospitals have thecapacity for primary PCI.
The advantage of primary PCI and an apparent prolongedtemporal margin of benefit have created a foundation forexpanding catheter-based reperfusion by transfer tocapable centers.
8/14/2019 braunwalds PCI for AMI
24/44
DANAMI-2The polarity of reperfusion strategy is exemplified by thefindings of two trials in this meta-analysis.
The DANAMI-2 randomized 1129 patients at referral
hospitals to on-site thrombolysis or transport for PCI (PCIdelay over thrombolysis was 67 minutes).
There was reduction in the composite endpoint of death,reinfarction, and stroke (8.5 vs. 14.2%, P=0.002), primarilybecause of less reinfarction (1.9 vs. 6.2%, P < 0.001).
Rescue PCI occurred in only 1.9%, and 4% of screenedpatients were considered unable to tolerate transport.
8/14/2019 braunwalds PCI for AMI
25/44
CAPTIM TrialAlternatively, the CAPTIM trial (N = 840) compared theearliest possible initiation of thrombolysis with directtransport for PCI. A physician initiated thrombolysis on site.
The composite endpoint (death, reinfarction, stroke)occurred in 6.2% with PCI and 8.2% with prehospitalthrombolysis (P=0.29). In patients randomized within 2hours, there was a trend for mortality reduction (2.2 vs.5.7%, P=0.058) with prehospital thrombolysis.
Cardiogenic shock occurred less frequently withthrombolysis in this early group (1.3 vs. 5.3%, P < 0.032).
Notably, in the thrombolytic group, rescue PCI occurred in26% and, by day 30, 70% underwent PCI.
8/14/2019 braunwalds PCI for AMI
26/44
Misc ConsiderationsOther factors should be considered with earlypresentation (shorter than 3 hours). Patientswith contraindications to thrombolysis and
those with cardiogenic shock should betransported for PCI.
Higher risk patients (e.g., anterior infarction,elderly, hemodynamic compromise) also
experience a larger benefit from catheter-based reperfusion, and the TIMI risk score canidentify this group.
Patients at higher risk for intracranialhemorrhage from thrombolysis will alsoaccrue less hazard from primary PCI.
8/14/2019 braunwalds PCI for AMI
27/44
Patients with 2- to 3-hour or longer presentation
delays will be better served by a primary PCIstrategy if transfer and/or reperfusion can beaccomplished promptly.
Despite ACC/AHA recommendations for atreatment interval (door to balloon) of less than90 minutes, another study from NRMI-3/4 onpatients transferred for PCI has determined amedian door to balloon time of 180 minutes, withonly 4.2% treated within 90 minutes.[
Clinical trials have demonstrated the feasibility ofrapid transport for primary PCI. Early assessmentusing prehospital 12-lead electrocardiogram (ECG)acquisition can allow efficient triage and advancepreparation at the PCI center, with a considerable
reduction in the treatment interval.
8/14/2019 braunwalds PCI for AMI
28/44
Impediments to
Widespread PCI Strategies.However, there are several impediments to
widespread application, especially in the UnitedStates, including lack of prehospital ECG
capability (10% in the United States), economicimpact on providers, organizational issues,regulatory policies involving certification,interpretation of performance metrics, and thepolitical dynamics of achieving a broad
consensus.Nevertheless, a geographic study has determined
that nearly 80% of the adult U.S. population liveswithin 60 minutes of a PCI-capable hospital.A recent AHA initiative is a step forward to
implement timely reperfusion via primary PCI in
8/14/2019 braunwalds PCI for AMI
29/44
THROMBOLYTIC-INELIGIBLE
PATIENTS.A significant proportion (25 to 30%) of patients
presenting with ST elevation (or LBBB) infarctionwho are eligible do not receive reperfusiontherapy.In the Global Registry of Acute Coronary Surgery
(GRACE) 2084 patients presenting within 12 hoursof STEMI onset, thrombolytic were CI in 15% and,overall, 30% of eligible patients did not receivereperfusion therapy.
Correlates of the latter group included those withprior bypass surgery, diabetes, history ofcongestive failure, and age older than 75 years.
There remains a bias against thrombolysis,particularly for the elderly.
Patients with clear-cut and relativecontraindications to thrombol sis are at hi her
8/14/2019 braunwalds PCI for AMI
30/44
PCI for Those with Lytic
CIPrimary PCI also achieved significant
myocardial salvage and a favorable 6-monthmortality in a group of patients ineligible for
thrombolysis.
Primary PCI can be applied to most higher riskpatients who are not ideal candidates forthrombolytic therapy.
The contraindications to primary angioplastyare limited to patients who cannot receiveheparin, aspirin, or thienopyridines,
documented life-threatening contrast allergy,or lack of vascular access.
PATIENTS IN CARDIOGENIC
8/14/2019 braunwalds PCI for AMI
31/44
PATIENTS IN CARDIOGENICSHOCK.Multiple observational series of patients
undergoing balloon angioplasty in cardiogenicshock have demonstrated improvedhemodynamic status and suggested enhancedsurvival.
In contrast, thrombolysis appears less effectivewhen administered to patients in shock.Although thrombolysis may provide a survival
benefit for patients, increasing rates of PCI (28 to54%) and declining rates of lytic use (20 to 6%)
were associated with declining mortality (60 to48%, P < 0.001) for 25,311 shock patients in theNRMI database from 1995 to 2004.In this propensity-adjusted multivariable analysis,
primary PCI was associated with a significantreduction in hospital mortality (OR, 0.46; 95% CI,0.40 to 0.53).
8/14/2019 braunwalds PCI for AMI
32/44
SHOCK TrialRandomized 302 patients to an early (within 12 hoursshock onset, 36 hours of infarction onset)revascularization strategy (PCI, 63%; bypass surgery38%) or medical stabilization (thrombolysis, 63%) with
delayed revascularization, if appropriate. IABP support was recommended (86%) in both groups.A significant survival advantage for early
revascularization was noted at 6 months and 1 yearbut not at the 30-day primary endpoint.
The 30-day mortality was significantly lower with earlyrevascularization for patients younger than 75 year.(41 vs. 57%, P < 0.05). There was no benefit for the 56patients older than 75 years, but an imbalance ofbaseline characteristics may have been present in thissmall group.
8/14/2019 braunwalds PCI for AMI
33/44
SHOCKFurthermore, in the larger SHOCK registry, hospitalmortality was significantly lower in elderly patientsselected for early revascularization (48 vs. 81%,P=0.0003) and similar to that of younger patients (45
vs. 61%, P=0.002).With exclusion of early deaths and covariate-adjusted
modeling, the relative risk with revascularization was0.46 (95% CI, 0.28 to 0.75; P=0.002) for age of 75years and 0.76 (95% CI, 0.59 to 0.99; P=0.045) for age
younger than 75 years.Rapid reperfusion is critical for survival and a large
benefit (132 lives saved/1000 treated) is realized at 1year.
Early revascularization is clearly recommended for
patients younger than 75 years and suitable for many
8/14/2019 braunwalds PCI for AMI
34/44
More Shocking ResultsThe survival of 82 patients undergoing PCI in
the SHOCK trial was 50% at 1 year.
One-year mortality was 38% with TIMI-3, 55%with TIMI-2, and 100% with TIMI 0-1 flow afterPCI.
The PCI success rate was 76%. Stents (34%)
and GP IIb/IIIa inhibitors (32%) were used inthe minority during the study period (1993 to1998).
A prospective registry of 96 shock patients
has indicated that the use of stents and-
8/14/2019 braunwalds PCI for AMI
35/44
Most cardiogenic shock patients have multivesseldisease (81% in SHOCK). Survival rates for PCIand bypass surgery in the early revascularization
arm were similar, although patients undergoingbypass surgery had more extensive coronarydisease and a higher prevalence of diabetes.[
There was a trend for improved 30-day survival in
bypass surgery patients with completerevascularization (63 vs. 17%, P=0.07).
Only 13% of PCI patients underwent a multivesselprocedure, with a 1-year survival of 20%
compared with 55% with single-vessel PCI.
8/14/2019 braunwalds PCI for AMI
36/44
Elderly +Lytics = Bad Jaeger
ShotAlthough the relative benefit of thrombolytic therapy isdiminished in the elderly, the higher overall mortalityresults in a greater absolute mortality reduction, asnoted in a meta-analysis of major trials.
Despite this evidence, age predicts failure to usereperfusion therapy.Observations from the Medicare and NRMI data bases
have indicated no benefit or possible harm for thisgroup with thrombolysis, especially in patients olderthan 75 to 80 years.
Apprehension regarding the risk of intracranialhemorrhage remains, and the cumulative risk factorsfor this complication are more common in the elderlypopulation.
Elderly patients undergoing thrombolysis have more
than a threefold risk of free wall rupture comparedwith no reperfusion or primary PCI.
8/14/2019 braunwalds PCI for AMI
37/44
Elderly + PCI = Sexy!In contrast, Medicare patients undergoing primaryangioplasty (N = 2038) exhibited a lower 30-day(8.7 vs. 11.9%, P=0.001) and 1-year (14.4 vs.
17.6%,P=
0.001) mortality compared withthrombolysis (N = 18,645). For patients older than 75 years in the NRMI-2
registry, the combined endpoint of death andnonfatal stroke was significantly higher in patients
treated with t-PA compared with primaryangioplasty (18.4 vs. 14.6%, P=0.001).In the PCAT analysis of 10 randomized trials,
primary angioplasty was more effective inreducing 30-day mortality in patients over age 70
years compared with younger patients.
8/14/2019 braunwalds PCI for AMI
38/44
Prior CABGMortality increased with prior CABG
Large thrombus burden in vein grafts mayalso be more resistant to lytic agents.
POBA of vein grafts assoc with higher rates ofTIMI-3 flow compared with lytics, but reducedcompared to native vessel reperfusion.
8/14/2019 braunwalds PCI for AMI
39/44
GP 2b/3a Inhibitors with
PTCARAPPORT (ReoPro in AMI Primary PTCA
Organization Randomized Trial) assignedpeople to either placebo or abciximab while
undergoing balloon angioplasty.
Incidence of death, reinfarction, or urgent TVRwas reduced significantly at 30 days (6% vs.11%) and 6 months with reopro.
8/14/2019 braunwalds PCI for AMI
40/44
Rescue AngioplastyLimited data regarding value of recue
angioplasty in pts who do not achievereperfusion after lytics.
Observation data showed suggested littlebenefit and high mortality in whom attemptedRA failed.
Analysis of 4 small randomized trials of RAidentified significant reduction in early severeHF, trend toward reduced mortality and 2 ofthese trials showed signif survival benefit at 1
year.
8/14/2019 braunwalds PCI for AMI
41/44
Facilitated AngioplastySeveral trials showed adverse outcomes if
early angioplasty (compared with delayed)after lytics with more complications (bypass
surgery and bleeding), a trend for highermortality, and no difference in LV function.
PACT (Plasminogen-activator AngioplastyCompatibility Trial) pts got dose tPA hadhigher TIMI-3 flow prior to angioplasty.
8/14/2019 braunwalds PCI for AMI
42/44
In ADMIRAL trial, reopro alone before cathresulted in TIMI-3 of only 30%.
However reopro combined with dose lyticsthe TIMI-3 flow rates were 62-77% without anincrease in major bleeding or ICH over fulldose lytics.
SPEED
8/14/2019 braunwalds PCI for AMI
43/44
Lytics for Late
PresentationIn the NRMI data base, nearly one third ofpatients with acute infarction presented morethan 12 hours after symptom onset.
Thrombolytic therapy in this group does notsignificantly improve survival.
Guidelines restrict recommendations for
reperfusion with PCI to late presentationpatients (12 to 24 hours) with persistentischemic symptoms, heart failure, andhemodynamic or electrical instability.
8/14/2019 braunwalds PCI for AMI
44/44
PCI for Late PresentationData from small RCTs evaluating the effect ofPCI more than 12 hours after MI are conflictingand inconclusive.
Recently, the BRAVE-2 trial (N = 365)evaluated immediate PCI in asymptomaticpatients 12 to 24 hours after symptom onset.
Scintigraphic infarct size was significantlysmaller in PCI patients (8 versus 13 percent, P< 0.001). Death, reinfarction, and stroke wereinsignificantly reduced with PCI at 30 days(4.4 versus 6.6 percent, P = 0.37).